Domača stran600812 • SHA
add
North China Pharmaceutical Co Ltd
Prejšnji trg. dan.
5,56 ¥
Dnevni razpon
5,53 ¥ - 5,60 ¥
Letni razpon
3,83 ¥ - 6,66 ¥
Povprečni obseg
18,86 mio.
Razm. P/E
119,92
Dividendna donosnost
0,18 %
Primarna borza
SHA
Borzne novice
Barron's
pred 1 dnevom
This ETF Has Returned 40% in 2024. Why It Can Beat the S&P 500 Again Next
Year.
0,38 %
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (CNY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 2,33 mrd. | −15,04 % |
Stroški poslovanja | 539,22 mio. | −19,20 % |
Čisti dohodek | 30,48 mio. | 2.035,14 % |
Čista dobičkovnost prihodkov | 1,31 | 2.520,00 % |
Earnings per share | — | — |
EBITDA | 362,65 mio. | 6,65 % |
Efektivna davčna stopnja | 32,92 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (CNY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 1,72 mrd. | 15,99 % |
Skupna sredstva | 21,71 mrd. | 0,92 % |
Skupne obveznosti | 15,10 mrd. | −0,95 % |
Celoten lastniški kapital | 6,61 mrd. | — |
Shares outstanding | 1,72 mrd. | — |
Razmerje P/B | 1,78 | — |
Donosnost sredstev | 2,06 % | — |
Donosnost kapitala | 2,47 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (CNY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 30,48 mio. | 2.035,14 % |
Denar iz dejavnosti | 175,21 mio. | −46,70 % |
Denar iz naložb | −153,19 mio. | 10,80 % |
Denar iz financiranja | −76,80 mio. | 67,74 % |
Neto sprememba denarnih sredstev | −55,38 mio. | 30,27 % |
Prost denarni tok | −660,87 mio. | −459,21 % |
Vizitka
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
Datum ustanovitve
20. dec. 1992
Zaposleni
10.159
